Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Gwenola Manic, Florine Obrist, Antonella Sistigu & Ilio Vitale. (2015) Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy. Molecular & Cellular Oncology 2:4.
Read now
Read now
Thomas P Matthews, Alan M Jones & Ian Collins. (2013) Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opinion on Drug Discovery 8:6, pages 621-640.
Read now
Read now
Articles from other publishers (31)
V. Aarthi & Indranil Chattopadhyay. 2024. Cancer Stem Cells and Signaling Pathways. Cancer Stem Cells and Signaling Pathways
119
133
.
Jérémy Ariey-Bonnet, Raphael Berges, Marie-Pierre Montero, Baptiste Mouysset, Patricia Piris, Kevin Muller, Guillaume Pinna, Tim W. Failes, Greg M. Arndt, Philippe Morando, Nathalie Baeza-Kallee, Carole Colin, Olivier Chinot, Diane Braguer, Xavier Morelli, Nicolas André, Manon Carré, Emeline Tabouret, Dominique Figarella-Branger, Marion Le Grand & Eddy Pasquier. (2023) Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. eBioMedicine 95, pages 104752.
Crossref
Crossref
Parisa Maleki Dana, Fatemeh Sadoughi, Hamed Mirzaei, Zatollah Asemi & Bahman Yousefi. (2022) DNA damage response and repair in the development and treatment of brain tumors. European Journal of Pharmacology 924, pages 174957.
Crossref
Crossref
Wei Wang, Yue Sun, Xiaobo Liu, Shaji K. Kumar, Fengyan Jin & Yun Dai. (2022) Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. Frontiers in Oncology 12.
Crossref
Crossref
Liesbeth Everix, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde & Julie Bolcaen. (2022) Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. Cancers 14:7, pages 1821.
Crossref
Crossref
Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Federica Bertolini, Michela Maur, Giorgia Guaitoli, Isca Chrystel, Uliano Morandi, Franco Stella, Massimo Dominici & Khawaja Husnain Haider. (2022) Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence. Cancers 14:4, pages 976.
Crossref
Crossref
Kiyohiro Ando, Miki Ohira, Ichiro Takada, Verna Cázares‐Ordoñez, Yusuke Suenaga, Hiroki Nagase, Shinichi Kobayashi, Tsugumichi Koshinaga, Takehiko Kamijo, Makoto Makishima & Satoshi Wada. (2021) FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis. Cancer Science 113:2, pages 587-596.
Crossref
Crossref
Tijana Vlatkovic, Marlon R. Veldwijk, Frank A. Giordano & Carsten Herskind. (2022) Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells. Cancers 14:3, pages 701.
Crossref
Crossref
Danielle P. Johnson, Mahesh B. Chandrasekharan, Marie Dutreix & Srividya Bhaskara. (2021) Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy. Cancers 13:3, pages 381.
Crossref
Crossref
Nazanin K Majd, Timothy A Yap, Dimpy Koul, Veerakumar Balasubramaniyan, Xiaolong Li, Sabbir Khan, Katilin S Gandy, W K Alfred Yung & John F de Groot. (2021) The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neuro-Oncology Advances 3:1.
Crossref
Crossref
Alessandra Ferri, Venturina Stagni & Daniela Barilà. (2020) Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. International Journal of Molecular Sciences 21:14, pages 4910.
Crossref
Crossref
Jian Zhu, Hanhui Zou, Wei Yu, Yuluan Huang, Bing Liu, Tao Li, Chengzhen Liang & Huimin Tao. (2019) Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells. Cancer Cell International 19:1.
Crossref
Crossref
Ítalo Faria do Valle, Giulia Menichetti, Giorgia Simonetti, Samantha Bruno, Isabella Zironi, Danielle Fernandes Durso, José C. M. Mombach, Giovanni Martinelli, Gastone Castellani & Daniel Remondini. (2018) Network integration of multi-tumour omics data suggests novel targeting strategies. Nature Communications 9:1.
Crossref
Crossref
Robert S. McNeill, Emily E. Stroobant, Erin Smithberger, Demitra A. Canoutas, Madison K. Butler, Abigail K. Shelton, Shrey D. Patel, Juanita C. Limas, Kasey R. Skinner, Ryan E. Bash, Ralf S. Schmid & C. Ryan Miller. (2018) PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. PLOS ONE 13:7, pages e0200014.
Crossref
Crossref
Ashley N. Gilbert, Joshua C. Anderson, Christine W. Duarte, Rachael S. Shevin, Catherine P. Langford, Raj Singh, G. Yancey Gillespie & Christopher D. Willey. (2018) Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions. Scientific Reports 8:1.
Crossref
Crossref
Zhaojun Qiu, Nancy L. Oleinick & Junran Zhang. (2018) ATR/CHK1 inhibitors and cancer therapy. Radiotherapy and Oncology 126:3, pages 450-464.
Crossref
Crossref
Nusrat Jahan, Jae M. Lee, Khalid Shah & Hiroaki Wakimoto. (2017) Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. International Journal of Cancer 141:8, pages 1671-1681.
Crossref
Crossref
Dimitrios Angelis & Maria Delivoria-Papadopoulos. (2017) Effects of Src kinase inhibition on expression of pro-caspase-2 after brain hypoxia in a piglet animal model. NeuroReport 28:12, pages 770-773.
Crossref
Crossref
Kai Huang, Jia Sun, Chao Yang, Yunfei Wang, Bingcong Zhou, Chunsheng Kang, Lei Han & Qixue Wang. (2017) HOTAIR upregulates an 18-gene cell cycle-related mRNA network in glioma. International Journal of Oncology.
Crossref
Crossref
Eric W. Prince, Ilango Balakrishnan, Monil Shah, Jean M. Mulcahy Levy, Andrea M. Griesinger, Irina Alimova, Peter S. Harris, Diane K. Birks, Andrew M. Donson, Nathan Davidson, Marc Remke, Michael D. Taylor, Michael H. Handler, Nicholas K. Foreman, Sujatha Venkataraman & Rajeev Vibhakar. (2016) Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget 7:33, pages 53881-53894.
Crossref
Crossref
G Balmus, P X Lim, A Oswald, K R Hume, A Cassano, J Pierre, A Hill, W Huang, A August, T Stokol, T Southard & R S Weiss. (2015) HUS1 regulates in vivo responses to genotoxic chemotherapies. Oncogene 35:5, pages 662-669.
Crossref
Crossref
Andrew J. Massey, Peter Stephens, Rebecca Rawlinson, Lauren McGurk, Ruth Plummer & Nicola J. Curtin. (2016) mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. Molecular Oncology 10:1, pages 101-112.
Crossref
Crossref
Y. Shen, M. Aoyagi-Scharber & B. Wang. (2015) Trapping Poly(ADP-Ribose) Polymerase. Journal of Pharmacology and Experimental Therapeutics 353:3, pages 446-457.
Crossref
Crossref
Adil I. DaudMichelle T. AshworthJonathan StrosbergJonathan W. GoldmanDavid MendelsonGregory SpringettAlan P. VenookSabine LoechnerLee S. RosenFrances ShanahanDavid ParryStuart ShumwayJennifer A. GrabowskyTomoko FreshwaterChristopher SorgeSoonmo Peter KangRandi IsaacsPamela N. Munster. (2015) Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 33:9, pages 1060-1066.
Crossref
Crossref
Vikash Kumar, Saman Khan, Priyanka Gupta, Namrata Rastogi, Durga Prasad Mishra, Shakil Ahmed & Mohammad Imran Siddiqi. (2014) Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents. Journal of Computer-Aided Molecular Design 28:12, pages 1247-1256.
Crossref
Crossref
Tomofumi Akasaka, Masahiko Tsujii, Jumpei Kondo, Yoshito Hayashi, Jin� Ying, Yuquan� Lu, Motohiko Kato, Takuya Yamada, Shunsuke� Yamamoto, Takuya Inoue, Yoshiki Tsujii, Akira Maekawa, Tetsuji Fujinaga, Eri� Shiraishi, Satoshi Hiyama, Takahiro Inoue, Shinichiro Shinzaki, Kenji� Watabe, Tsutomu� Nishida, Hideki Iijima & Tetsuo Takehara. (2014) 5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase�1 in p53‑mutated colon cancer cells. International Journal of Oncology.
Crossref
Crossref
Arunee Hematulin, Daniel Sagan, Kanlayanee Sawanyawisuth, Wunchana Seubwai & Sopit Wongkham. (2014) Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines. International Journal of Oncology.
Crossref
Crossref
M Signore, F Pelacchi, S di Martino, D Runci, M Biffoni, S Giannetti, L Morgante, M De Majo, E F Petricoin, L Stancato, L M Larocca, R De Maria, R Pallini & L Ricci-Vitiani. (2014) Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death & Disease 5:5, pages e1223-e1223.
Crossref
Crossref
Xiaoping Zhang, Hua Lv, Qingyu Zhou, Rana Elkholi, Jerry E. Chipuk, M.V. Ramana Reddy, E. Premkumar Reddy & James M. Gallo. (2014) Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models. Molecular Cancer Therapeutics 13:5, pages 1105-1116.
Crossref
Crossref
Todd M. Pitts, S. Lindsey Davis, S. Gail Eckhardt & Erica L. Bradshaw-Pierce. (2014) Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. Pharmacology & Therapeutics 142:2, pages 258-269.
Crossref
Crossref
Yun Dai, Shuang Chen, Liang Yi & Minhui Xu. 2013. Trends in Stem Cell Proliferation and Cancer Research. Trends in Stem Cell Proliferation and Cancer Research
591
654
.